Innoviva (INVA) reported $411M in revenue for fiscal 2025, +14.7% year on year. That ranks #2335 by revenue among 2853 SEC filers and #227 in Healthcare. Net income was $271M, a net margin of 65.9%. Revenue has grown 22.3% a year on average since 2011 ($24.5M then). The fiscal 2025 balance sheet shows $1.6B in total assets, $551M in cash and $258M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $411M | +14.7% | FY20252025-12-31 |
| Gross profitGrossProfit | $308M | +3.9% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $164M | −1.9% | FY20252025-12-31 |
| Net incomeProfitLoss | $271M | +1,059.2% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $197M | +4.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.1M | +318.9% | FY20252025-12-31 |
| Total assetsAssets | $1.6B | +25.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.2B | +69.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $551M | +80.7% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $258M | +0.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $98.0M | $187M | Open → |
| Q2 20262026-06-30 | $120M | −$83.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Innoviva, Inc.
- Ticker
- INVA
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001080014
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| ArtivionAORT | $441M | $9.8M |
| Genedx HoldingsWGS | $428M | −$21.0M |
| Mimedx GroupMDXG | $419M | $48.6M |
| InnovivaINVA | $411M | $271M |
| ArdelyxARDX | $407M | −$62.0M |
| Immunocore HoldingsIMCR | $400M | −$35.5M |
| Krystal BiotechKRYS | $389M | $205M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Innoviva — Key figures |url=https://companiesranked.com/en/company/innoviva |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Innoviva — Key figures. CompaniesRanked. https://companiesranked.com/en/company/innovivaBibTeX
@misc{companiesranked-en-company-innoviva-2026,
author = {{CompaniesRanked}},
title = {{Innoviva — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/innoviva}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-071776 · February 25, 2026
{{cite web |title=Innoviva — Key figures — 10-K (0001193125-26-071776) |url=https://www.sec.gov/Archives/edgar/data/1080014/000119312526071776/inva-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.